FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386002945> ?p ?o ?g. }

• W4386002945 endingPage "100792" @default.
• W4386002945 startingPage "100792" @default.
• W4386002945 abstract "Despite its use to prevent acute rejection, lifelong immunosuppression can adversely impact long-term patient and graft outcomes. In theory, immunosuppression withdrawal is the ultimate goal of kidney transplantation, and is made possible by the induction of immunological tolerance. The purpose of this paper is to review the safety and efficacy of immune tolerance induction strategies in living-donor kidney transplantation, both chimerism-based and non-chimerism-based. The impact of these strategies on transplant outcomes, including acute rejection, allograft function and survival, cost, and immune monitoring, will also be discussed.Databases such as PubMed, Scopus, and Web of Science, as well as additional online resources such as EBSCO, were exhaustively searched. Adult living-donor kidney transplant recipients who developed chimerism-based tolerance after concurrent bone marrow or hematopoietic stem cell transplantation or those who received non-chimerism-based, non-hematopoietic cell therapy using mesenchymal stromal cells, dendritic cells, or regulatory T cells were studied between 2000 and 2021. Individual sources of evidence were evaluated critically, and the strength of evidence and risk of bias for each outcome of the transplant tolerance study were assessed.From 28,173 citations, 245 studies were retrieved after suitable exclusion and duplicate removal. Of these, 22 studies (2 RCTs, 11 cohort studies, 6 case-control studies, and 3 case reports) explicitly related to both interventions (chimerism- and non-chimerism-based immune tolerance) were used in the final review process and were critically appraised. According to the findings, chimerism-based strategies fostered immunotolerance, allowing for the safe withdrawal of immunosuppressive medications. Cell-based therapy, on the other hand, frequently did not induce tolerance except for minimising immunosuppression. As a result, the rejection rates, renal allograft function, and survival rates could not be directly compared between these two groups. While chimerism-based tolerance protocols posed safety concerns due to myelosuppression, including infections and graft-versus-host disease, cell-based strategies lacked these adverse effects and were largely safe. There was a lack of direct comparisons between HLA-identical and HLA-disparate recipients, and the cost implications were not examined in several of the retrieved studies. Most studies reported successful immunosuppressive weaning lasting at least 3 years (ranging up to 11.4 years in some studies), particularly with chimerism-based therapy, while only a few investigators used immune surveillance techniques. The studies reviewed were often limited by selection, classification, ascertainment, performance, and attrition bias.This review demonstrates that chimerism-based hematopoietic strategies induce immune tolerance, and a substantial number of patients are successfully weaned off immunosuppression. Despite the risk of complications associated with myelosuppression. Non-chimerism-based, non-hematopoietic cell protocols, on the other hand, have been proven to facilitate immunosuppression minimization but seldom elicit immunological tolerance. However, the results of this review must be interpreted with caution because of the non-randomised study design, potential confounding, and small sample size of the included studies. Further validation and refinement of tolerogenic protocols in accordance with local practice preferences is also warranted, with an emphasis on patient selection, cost ramifications, and immunological surveillance based on reliable tolerance assays." @default.
• W4386002945 created "2023-08-20" @default.
• W4386002945 creator A5008187320 @default.
• W4386002945 creator A5022603494 @default.
• W4386002945 creator A5060412832 @default.
• W4386002945 creator A5063008501 @default.
• W4386002945 date "2023-12-01" @default.
• W4386002945 modified "2023-10-12" @default.
• W4386002945 title "Hematopoietic cell-based and non-hematopoietic cell-based strategies for immune tolerance induction in living-donor renal transplantation: A systematic review" @default.
• W4386002945 cites W1511438228 @default.
• W4386002945 cites W1523702731 @default.
• W4386002945 cites W1524999411 @default.
• W4386002945 cites W1543497746 @default.
• W4386002945 cites W1558094622 @default.
• W4386002945 cites W1560656207 @default.
• W4386002945 cites W1580156494 @default.
• W4386002945 cites W1604538830 @default.
• W4386002945 cites W1643655877 @default.
• W4386002945 cites W1761108822 @default.
• W4386002945 cites W1910012553 @default.
• W4386002945 cites W1941682190 @default.
• W4386002945 cites W1944874974 @default.
• W4386002945 cites W1949227094 @default.
• W4386002945 cites W1965994170 @default.
• W4386002945 cites W1967702267 @default.
• W4386002945 cites W1977121422 @default.
• W4386002945 cites W1978865331 @default.
• W4386002945 cites W1978994698 @default.
• W4386002945 cites W1980690619 @default.
• W4386002945 cites W1981004692 @default.
• W4386002945 cites W1981631137 @default.
• W4386002945 cites W1983215753 @default.
• W4386002945 cites W1988958344 @default.
• W4386002945 cites W1994160001 @default.
• W4386002945 cites W1998039712 @default.
• W4386002945 cites W2000133923 @default.
• W4386002945 cites W2000676524 @default.
• W4386002945 cites W2001260531 @default.
• W4386002945 cites W2004708987 @default.
• W4386002945 cites W2007631222 @default.
• W4386002945 cites W2009385866 @default.
• W4386002945 cites W2010912590 @default.
• W4386002945 cites W2013436922 @default.
• W4386002945 cites W2018258390 @default.
• W4386002945 cites W2021282723 @default.
• W4386002945 cites W2023003954 @default.
• W4386002945 cites W2024326908 @default.
• W4386002945 cites W2025294489 @default.
• W4386002945 cites W2025371271 @default.
• W4386002945 cites W2026309746 @default.
• W4386002945 cites W2026399893 @default.
• W4386002945 cites W2027488189 @default.
• W4386002945 cites W2027961016 @default.
• W4386002945 cites W2028239901 @default.
• W4386002945 cites W2034079017 @default.
• W4386002945 cites W2039801541 @default.
• W4386002945 cites W2040775375 @default.
• W4386002945 cites W2041687279 @default.
• W4386002945 cites W2044875340 @default.
• W4386002945 cites W2045462253 @default.
• W4386002945 cites W2047774290 @default.
• W4386002945 cites W2050875930 @default.
• W4386002945 cites W2056210319 @default.
• W4386002945 cites W2058044331 @default.
• W4386002945 cites W2059331690 @default.
• W4386002945 cites W2060437379 @default.
• W4386002945 cites W2066300055 @default.
• W4386002945 cites W2068205868 @default.
• W4386002945 cites W2070247501 @default.
• W4386002945 cites W2073790106 @default.
• W4386002945 cites W2076491580 @default.
• W4386002945 cites W2078633109 @default.
• W4386002945 cites W2079367065 @default.
• W4386002945 cites W2085582924 @default.
• W4386002945 cites W2085940798 @default.
• W4386002945 cites W2086516001 @default.
• W4386002945 cites W2087358242 @default.
• W4386002945 cites W2089676458 @default.
• W4386002945 cites W2091936488 @default.
• W4386002945 cites W2094607403 @default.
• W4386002945 cites W2095107385 @default.
• W4386002945 cites W2097228520 @default.
• W4386002945 cites W2103114237 @default.
• W4386002945 cites W2105872611 @default.
• W4386002945 cites W2106072740 @default.
• W4386002945 cites W2106951989 @default.
• W4386002945 cites W2107841942 @default.
• W4386002945 cites W2111722073 @default.
• W4386002945 cites W2116169090 @default.
• W4386002945 cites W2117002902 @default.
• W4386002945 cites W2117600377 @default.
• W4386002945 cites W2118808528 @default.
• W4386002945 cites W2119322191 @default.
• W4386002945 cites W2123252570 @default.
• W4386002945 cites W2124927041 @default.
• W4386002945 cites W2126087394 @default.
• W4386002945 cites W2126468249 @default.
• W4386002945 cites W2127001878 @default.

• next